Law & Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law & Health Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Eisai and Pfizer

Hope for Mild Alzheimer's Patients as House of Lords Refuses to Hear NICE's Appeal

hydrochloride) and Pfizer Limited, its co-promotion partner, welcome the announcement by the House of Lords that they have refused the National Institute for Health and Clinical Excellence (NICE)'s application for leave to appeal against the Court of Appeal verdict handed down earlier this year.

In May this year the Court of Appeal found in favour of Eisai, and ruled that the process by which NICE decided to restrict anti-dementia medicines for newly diagnosed patients with mild Alzheimer's disease was procedurally unfair and that it put stakeholders at a significant disadvantage in their...

• View Other Issues of Law & Health Weekly
  
• View Other NewsRx Publications